Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Vancomycin-Resistant Enterococcus faecium Infections Pipeline Review, H2 2016: Therapeutics Analysis by Stage of Development, Drug Target, MoA, RoA & Molecule Type

Wednesday, November 30, 2016 3:11
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Vancomycin-Resistant Enterococcus faecium Infections Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Vancomycin-Resistant Enterococcus faecium Infections therapeutics industry report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects.

 

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Browse more detail information about Vancomycin-Resistant Enterococcus faecium Infections market report at: http://www.absolutereports.com/vancomycin-resistant-enterococcus-faecium-infections-pipeline-review-h2-2016-10435015

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2016:

  • Alchemia Limited
  • Alvogen Korea Co., Ltd.
  • Aphios Corporation
  • C3 Jian, Inc
  • Cellceutix Corporation
  • Helix BioMedix, Inc.
  • Hsiri Therapeutics LLC
  • LegoChem Biosciences, Inc
  • Lytix Biopharma AS
  • MGB Biopharma Limited
  • MicuRx Pharmaceuticals, Inc.
     

Get a PDF Sample of Vancomycin-Resistant Enterococcus faecium Infections Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10435015

Drug Profiles of Included in Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Development Market Report

  • AM-218
  • BDM-I
  • Chrysophaentin
  • Closthioamide
     

And other drug profiles
Have any query? ask our expert @
http://www.absolutereports.com/enquiry/pre-order-enquiry/10435015

Key Topics Covered:
1.Introduction
2.Vancomycin-Resistant Enterococcus faecium Infections Overview
3.Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Development
4.Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections – Overview
5.Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections – Comparative Analysis
6.Vancomycin-Resistant Enterococcus faecium Infections – Therapeutics under Development by Companies
7.Vancomycin-Resistant Enterococcus faecium Infections – Therapeutics under Investigation by Universities/Institutes
8.Vancomycin-Resistant Enterococcus faecium Infections Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Vancomycin-Resistant Enterococcus faecium Infections – Products under Development by Companies
13.Vancomycin-Resistant Enterococcus faecium Infections – Products under Investigation by Universities/Institutes
14.Vancomycin-Resistant Enterococcus faecium Infections – Companies Involved in Therapeutics Development
15.Vancomycin-Resistant Enterococcus faecium Infections Drug Profiles
16.Vancomycin-Resistant Enterococcus faecium Infections Dormant Projects
17.Vancomycin-Resistant Enterococcus faecium Infections Discontinued Products
18.Vancomycin-Resistant Enterococcus faecium Infections Featured News & Press Releases
And Continue…

Get Discount on Vancomycin-Resistant Enterococcus faecium Infections Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10435015

List of Tables

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2016
  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections – Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016

 

List of Figures

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2016
  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections – Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016 39
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 41
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 41
  • Number of Products by Routes of Administration, H2 2016 43
  • Number of Products by Stage and Routes of Administration, H2 2016 43
  • Number of Products by Molecule Types, H2 2016 45

Number of Products by Stage and Molecule Types, H2 2016 45

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.